WCN26-7392 Efficacy and Safety of MT1013 compared to Etelcalcetide in patients with Secondary Hyperparathyroidism undergoing Maintenance Dialysis

Read full text Summarise with VIRAT
Authors: Ping Zhang, Jianghua Chen, Bing Wang, Xiangling Wang, Linyuan Wang, Zhian Huang, Yu Zhi, Lanlan Song, Ruiling Wang, Xiaodong Wang, Hao Yu, Chong Luo
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

MT1013 is a first-in-class dual agonist targeting both the calcium-sensing receptor (CaSR) and osteogenic growth peptide (OGP). It is indicated for the treatment of SHPT in patients undergoing maintenance dialysis. In addition to its action on CaSR, MT1013 engages OGP—a target that promotes mesenchymal stem cell differentiation into osteoblasts and enhances bone formation. This dual mechanism further assists in regulating levels of iPTH, calcium, and phosphorus.

Fields of Study & Subjects

Parathyroid Disorders and Treatments Dialysis and Renal Disease Management Thyroid and Parathyroid Surgery

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104265–104265
Publication date
25 March 2026
Language
EN